Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.
Research Interests

Papers共 25 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Abstract 6512: BPI-501836: A highly potent small molecule inhibitor targeting KRASG12D mutation
Xiang Yang, Yuan Lu, Renqi Xu, Xiaoqiang Kong, Yongqing Sun, Xingjie Zhu, Xiaoyun Liu,Zhengyao Zou,Haibo Chen, Yanju Liu, Jialing Sun, Han Han,
Cancer Researchno. 6_Supplement (2024): 6512-6512
Cited0Views0Bibtex
0
0
Abstract CT142: Phase 1 study of BPI-23314, a novel BET inhibitor and degrader, in advanced myeloid leukemia (AML)
Mingyuan Sun, Xiangyu Jin, Jing Guo, Xiaoyun Liu, Yan Xu,Hong Lan,Jiabing Wang, Jiangnan Zhen, Jing Yang,Lieming Ding,Junyuan Qi
Cancer Researchno. 7_Supplement (2024)
Cited0Views0Bibtex
0
0
Abstract 6513: Discovery and characterization of a KRASG12C/D/V degrader with potent anti-tumor activity in KRASmut-driven preclinical models
Zhengqing Li, Renqi Xu, Xiaofeng Yang,Zhengyao Zou, Xiaoqiang Kong,Haibo Chen, Yongqing Sun, Ying Zhao, Jing Guo, Cheng Yang, Han Han, Xiaoyun Liu,
Cancer Researchno. 6_Supplement (2024): 6513-6513
Cited0Views0Bibtex
0
0
Abstract 7575: BPI-460372, a covalent, irreversible TEAD inhibitor in Phase I clinical development
Xiaohong Han, Jing Guo, Xiangyu Jin, Lingyin Zhu,Hongling Shen, Xiaofeng Xu, Mengjie Zhang, Xiaoyun Liu, Yanju Liu, Hongke Cheng, Shunna Guo,Lieming Ding,
Cancer Researchno. 6_Supplement (2024): 7575-7575
Cited0Views0Bibtex
0
0
Abstract 6511: BPI-520105, a highly potent, CNS-penetrant 4th generation EGFR inhibitor overcoming major EGFR resistance mutations in NSCLC
Jing Guo,Lijia Liu,Xiangyong Liu,Bang Fu, Guangcan Bai, Changyong Qiu, Wei Ren, Xiaodong Song, Guolong Du, Xiao Sun, Yongchun Zhang, Weidong Cai,
Cancer Researchno. 6_Supplement (2024): 6511-6511
Cited0Views0Bibtex
0
0
Abstract 7583: Discovery of a potent small molecule MALT1 protease inhibitor for the treatment of cancer
Yuzhen Zhou,Bang Fu,Jie Chen, Weidong Cai, Xiao Sun,Yinlong Li, Wei Ren, Qichao Shen, Guolong Du, Xiaojun Zhou,Zhengyao Zou,Haibo Chen,
Cancer Researchno. 6_Supplement (2024): 7583-7583
Cited0Views0Bibtex
0
0
Abstract 6510: BPI-511966,a potent and selective HPK1 inhibitor with robust single-agent efficacy for cancer immunotherapy
Yong Zhang, Xiaoguan Zhu,Wenmao Wu, Zhifang Xia,Zhengyao Zou, Han Han, Cheng Yang,Haibo Chen,Tianyi Ma, Xiaoyun Liu, Jing Guo, Hao Wu,
Cancer Researchno. 6_Supplement (2024): 6510-6510
Cited0Views0Bibtex
0
0
Discovery & preclinical evaluation of BPB-101: A novel triple functional bi-specific antibody targeting GARP-TGF complex/SLC, free TGF- and PD-L1
Wenxin Xu, Jieying Xu, Deyu Xu, Hongjie Cheng,Li Zhang, Huan Zheng, Siyuan Ye, Mengshi Jiang,Jiabing Wang,Lieming Ding
CANCER RESEARCHno. 7 (2023)
Cited0Views0Bibtex
0
0
Discovery of BPI460372, a potent and selective inhibitor of TEAD for the treatment of solid tumors harboring Hippo pathway aberrations
Hongling Shen, Xiaofeng Xu, Hongfei Rong, Xizhen Song, Jinheng Gao,Jie Chen,Di Zhu, Xiangdong Zhao, Jun Tong,Zhengyao Zou, Xiaoyun Liu, Jin Guo,
CANCER RESEARCHno. 7 (2023)
Cited0Views0Bibtex
0
0
Load More
Author Statistics

#Papers: 26

#Citation: 1

H-Index: 1

G-Index: 1

Sociability: 5

Diversity: 0

Activity: 0

  • 合作者
  • 学生
  • 导师
No result temporarily, you can search similar Scholar with the same research interest
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn